This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Belcaro, G. V. Articles by Grimaldi, R. Search for Related Content PubMed PubMed Citation Articles by Belcaro, G. V. Articles by Grimaldi, R. Social Bookmarking                         What's this?

Capillary Filtration and Ankle Edema in Patients with Venous Hypertension Treated with TTFCA

Cardiovascular Clinic, University G. D'Annunzio, Chieti, Italy, Irvine Cardiovascular Laboratory, St. Mary's Hospital Medical School, London, U.K.

Alex Rulo, M.D.

Irvine Cardiovascular Laboratory, St. Mary's Hospital Medical School, London, U.K.

Roberto Grimaldi, M.D.

Scharper Spa, Milan, Italy

The variation of capillary filtration rate (CFR), ankle circumference (AC), and ankle edema (AE) was evaluated in three groups of patients with venous hypertension (ambulatory venous pressure > 42 mmHg) and in a group of normal subjects before and after treatment for four weeks with Total Triterpenic fraction of Centella Asiatica (TTFCA), a venoactive drug acting on the microcirculation and on capillary permeability. Group A (20 patients) was treated with TTFCA 60 mg tid; Group B (20 patients) was treated with 30 mg tid; Group C (12 patients) was treated with placebo; and Group D (10 normal subjects) was treated with TTFCA 60 mg tid in an open study.

Capillary filtration rate was assessed by venous occlusion plethysmography, ankle edema by a new system called AECT (Ankle edema coin tester). Subjective symptoms of venous hypertension were assessed by an analogue scale line considering four symptoms: swelling sensation, restless lower extremity, pain and cramps, and tiredness. CFR, AC, and AE were significantly higher in patients in comparison with normal subjects.

After four weeks of TTFCA treatment there was a significant decrease of the abnormally increased CFR, AC, and AECT time in patients.

This was also greater in the higher dose group. No significant change was observed in the placebo group and in normal subjects treated with TTFCA. Symptoms were also significantly improved in the two groups treated with the active drug according to the dose. No significant changes were observed in the placebo group.

In conclusion the improvement of symptoms by TTFCA observed in patients with venous hypertension was well correlated with the improvement of CFR and ankle edema, and dose ranging showed that 180 mg/day is more effective in improving both symptoms and CFR.

Angiology, Vol. 41, No. 1, 12-18 (1990)
DOI: 10.1177/000331979004100102


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?